Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2026)

Aquestive Therapeutics' Capital Expenditures history runs 10 years deep, the most recent figure standing at $52000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 61.48% year-over-year to $52000.0; the TTM figure through Mar 2026 stood at $479000.0 (up 80.75% YoY), while the FY2025 annual figure was $562000.0, up 253.46% from the prior year.
• Capital Expenditures was $52000.0 for Q1 2026 at Aquestive Therapeutics, down from $85000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $826000.0 in Q2 2023 to a low of -$52000.0 in Q2 2025.
• Historically, Capital Expenditures has averaged $164235.3 across 5 years, with a median of $85000.0 in 2025.
• Biggest YoY gain for Capital Expenditures was 1350.0% in 2024; the steepest drop was 103.51% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $26000.0 in 2022, then tumbled by 38.46% to $16000.0 in 2023, then declined by 6.25% to $15000.0 in 2024, then soared by 466.67% to $85000.0 in 2025, then slumped by 38.82% to $52000.0 in 2026.
• The last three Capital Expenditures figures came in at $52000.0 (Q1 2026), $85000.0 (Q4 2025), and $394000.0 (Q3 2025), per Business Quant data.